Tag: # Ibrutinib

Introduction: Pure Red Cell Aplasia (PRCA) is a recognized complication following major ABO-incompatible allogeneic stem cell transplantation (HSCT). Characterized by anemia, reticulocytopenia, and the absence of erythroblasts in the bone marrow, PRCA can significantly impact patient outcomes. Recent research explores Ibrutinib as a novel therapeutic option for managing PRCA post-HSCT, showing promising results in restoring…